Geneva, Switzerland (PRWEB) April 23, 2014
Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today the Company’s chief scientific officer, Pierre-Alain Girod, Ph.D., will be speaking on overcoming complex secretion bottlenecks in his talk, “Proprietary and Unique Expression System for Versatile and Ubiquitous Transgene Expression” at the 2014 PEGS Summit on Wednesday, May 7, 2014 at the Seaport World Trade Center in Boston, Massachusetts. Selexis will also be exhibiting at the conference, May 5 – 9, 2014.
Dr. Girod’s lecture is part of the Antibody Engineering track. Conference attendees can hear Dr. Girod’s lecture on Wednesday, May 7 at 12:10 PM.
“Proprietary and Unique Expression System for Versatile and Ubiquitous Transgene Expression”
Based on proprietary epigenetic DNA regulator elements and leveraging the SURE CHO-M Genome and Transcriptome, Selexis has developed a novel platform approach for the generation of CHO cell lines. By combining robust transcription with a library approach to debottlenecking translation, folding and secretion, Selexis has launched the SURE CHOM-Mplus™ Libraries. This technology has an extensive history of generating high-level, stable expressing cell lines, including cell lines producing difficult-to-express proteins such as Fc-fusions and large multimeric proteins. The extensive characterization of the CHO-M cell line supports comprehensive and effective transfer packages for manufacturing.
Additionally, conference attendees can meet with Selexis representatives at Booth 329, May 5 - 9. To schedule meetings in advance, please contact Selexis at SURE(at)selexis(dot)com.
Registration for the PEGS conference is required. For more information, visit http://www.pegsummit.com/
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:
# # #